|
|
 |
|
Viewing report
|
|
|
|
Industry Insight - Indian Biopharma
CYGNUS Business Consulting & Research, Nov 2010, Pages: 205
Biopharmaceuticals are complex macromolecules (Large molecules) created through the genetic manipulation of living organisms using gene cloning, recombinant DNA (gene splicing), or cell fusion technologies. The total Biopharma industry grew by 12% over FY 2008-09 to Rs88.28 billion in 2009-10.
The total bio-pharma industry, consisting of therapeutics, vaccines, diagnostics, and other products such as statins, and continues to be largest contributor to the overall biotech market in the country. The good performance of the bio-pharma sector is attributed to the strongly growing vaccine business which accounted for about 51% of the total bio-pharma business in fiscal year 2010. Interestingly, India is one of the largest producers of traditional vaccines in the world.
The life science sector is emerging as a key industrial segment in the national economy. India is counted among the top 12 global biotech hotspots and is the 3rd largest in Asia Pacific (in terms of number of biotech companies). The Regulatory framework in Biotechnology is undergoing a huge revamp and hence the Biopharma sector is also expected to be affected by it. Though there are no specifically separate Regulations and Policies for the Biopharma sector all the aspects of the upcoming Biotech Policy which will affect the sector are discussed in the report. The emerging positive trends in India offer a potential solution to some of these problems. There are seven key broad areas to leverage the advantages that India offers to the established pharma and biotech industries. These include contract research, R&D alliances, clinical trials, R&D for neglected diseases, in-licensing of preclinical as well as early clinical drug candidates, IT applications and data management and herbal heritage.
The above background initiated need for a comprehensive Industry Insight on Indian Biopharma. Overview of The Indian Biopharma in India with a brief preamble of Industry Overview is discussed in the beginning along with its Segmental analysis of biopharma industry according to its Vaccines, Diagnostics and Therapeutics. application of growth drivers, issues and challenges, core technologies, major players, regulatory environment, Critical success factors, emerging trends and opportunities in india is discussed in total 10 chapters.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
